Loading...

What we offer

Profound expertise

With decades of experience, we leverage our deep understanding of the global pharmaceutical markets, industry trends, and technologies for our target markets.

quality execution

We leverage resources dynamically to support impeccable execution that is observed throughout the value chain commencing from R&D to commercialisation.

Smart portfolio

Our robust evaluation process is aimed at creating a balanced portfolio of niche and complex products for multiple geographies.

RELIABLE PRODUCT DELIVERY

Our end-to-end delivery model is supported by a growing network of manufacturing, quality and service infrastructure globally.

  • 50+ active projects
  • 200+ scientists
  • 9+ NDAs
  • 15+ patents

Our portfolio

Complex products

Key assets

  • STRONG TEAM WITH DEMONSTRATED DELIVERY FROM CONCEPT TO APPROVAL

  • PRIMARY FOCUS ON LIQUID INJECTABLES, NANO EMULSIONS AND DRUG/DEVICE COMBINATIONS

  • SEVERAL FORMULATIONS AND DOSAGE FORMS ARE FIRST-IN-THE-WORLD

  • VALUE CREATION THROUGH INNOVATION AND IP PROTECTION

Intensive characterisation

We have a strong understanding of the regulatory and clinical requirements across the globe.

Capabilities from complex analytical techniques to the characterisation of product-specific attributes & API sameness.

Aligning API characteristics with dosage and delivery forms.

THERAPEUTICALLY RELEVANT INNOVATIONS

Portfolio to address un/undermet needs of the healthcare professionals and patients around the world

Innovation targeted at new indications to improve therapeutic outcomes and novel dosage forms to improve compliance and/or safety

Harnessing power of in-vitro models and analytical science for abridged clinical/regulatory pathways

Pipeline

15+ APIS

  • IN-HOUSE DEVELOPMENT of complex, critical or low availability APIs, ensuring long term cost competitiveness and supply chain continuity

  • Our APIs are predominantly manufactured at EU GMP, PMDA AND USFDA ACCREDITED SITES

50+ Formulations

  • Injectables

  • Topicals (including oncology and hormonals)

  • Complex oral solids, liquids and suspensions

  • Drug-Device Combinations and Peptides

Our GMP capabilities

Non-Sterile
Sterile

Oral solid

Semi solid

Hi-Pot. Semi solid

Suppositoria

Liquid

Onco Oral solid

Cephalosporins

Mono-bactam

Onco Lyo

Onco Liq

Liquid

Lyo

Bags

Latina Pharma SPA
Italy
Bafna PVT. LTD
India
Katsuyama Pharma KK
Japan
Kavis Pharma LLC
USA
Pharma Pack LTD
Hungary

Distribution hub, late-stage customization and serialization for global markets

Current capabilities

Planned in 2023-2024